Estrogen Replacement Therapy and Stroke Risk
Because of the increased incidence of stroke that is sometimes observed with HRT, neurologists are often asked to consult with prescribing physicians to assess stroke risk.
BRIEF COMMUNICATION
Hormone replacement therapy after menopause is not a simple topic. Among other health implications, the risk of stroke events in postmenopausal women with or without hormone replacement therapy (HRT) is not clear. Efforts have been made to assess the risks and benefits of hormone replacement therapy after menopause. The most well-defined benefits are related to prevention of osteoporosis and bone fractures as well as the reduction of menopausal and post-menopausal symptoms. Risks of HRT include malignancy (especially breast cancer) and cardiovascular events (eg, myocardial infarction, stroke, venous thromboembolism).
Researchers in another
The mechanism by which HRT could increase the risk of stroke had been extensively studied, and there are some answers-but there are some unanswered questions as well. Before the onset of menopause, women have a lower incidence of stroke than men of the same age. Because women experience a higher stroke rate than age-matched men after menopause, estrogen, the most obvious physiological change in women after menopause, could have an influence on this incidence. Yet, estrogen replacement therapy has been noted to increase the incidence of cardiac events and stroke. And that is where the question of mechanism gets more complicated.
Several studies show that estrogen receptors may become less sensitive to estrogen after a period of time, during which there has been lower exposure to estrogen. This diminished response has been hypothesized to be an explanation for the fact that women who begin HRT later do not experience a protective effect. But it does not explain the increased incidence of stroke that is sometimes observed with HRT.
Patient care implications after stroke
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS)3 recommends that doctors follow a patient-specific and tailored approach to HRT decision-making. NAMS
While neurologists do not initiate or make decisions about HRT, stroke risk plays a role in the decision-making process. Neurologists could be asked to assess stroke risk when physicians who prescribe HRT are making risk/benefit decisions.
References:
1. Carrasquilla GD, Frumento P, Berglund A, et al.
2. Løkkegaard E, Nielsen LH, Keiding N.
3. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025